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Abstract
Background: Accelerometric analysis of gait abnormalities in golden retriever muscular dystrophy (GRMD) dogs is
of limited sensitivity, and produces highly complex data. The use of discriminant analysis may enable simpler and
more sensitive evaluation of treatment benefits in this important preclinical model.
Methods: Accelerometry was performed twice monthly between the ages of 2 and 12 months on 8 healthy and
20 GRMD dogs. Seven accelerometric parameters were analysed using linear discriminant analysis (LDA). Manipulation
of the dependent and independent variables produced three distinct models. The ability of each model to detect gait
alterations and their pattern change with age was tested using a leave-one-out cross-validation approach.
Results: Selecting genotype (healthy or GRMD) as the dependent variable resulted in a model (Model 1) allowing a
good discrimination between the gait phenotype of GRMD and healthy dogs. However, this model was not sufficiently
representative of the disease progression. In Model 2, age in months was added as a supplementary dependent
variable (GRMD_2 to GRMD_12 and Healthy_2 to Healthy_9.5), resulting in a high overall misclassification rate (83.2%).
To improve accuracy, a third model (Model 3) was created in which age was also included as an explanatory variable.
This resulted in an overall misclassification rate lower than 12%. Model 3 was evaluated using blinded data pertaining
to 81 healthy and GRMD dogs. In all but one case, the model correctly matched gait phenotype to the actual
genotype. Finally, we used Model 3 to reanalyse data from a previous study regarding the effects of
immunosuppressive treatments on muscular dystrophy in GRMD dogs. Our model identified significant effect of
immunosuppressive treatments on gait quality, corroborating the original findings, with the added advantages of
direct statistical analysis with greater sensitivity and more comprehensible data representation.
Conclusions: Gait analysis using LDA allows for improved analysis of accelerometry data by applying a
decision-making analysis approach to the evaluation of preclinical treatment benefits in GRMD dogs.
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Background
Duchenne muscular dystrophy (DMD) is an X-linked
disorder caused by various mutations in the gene en-
coding for dystrophin, resulting in the absence of the
functional protein in muscle fibres [1]. DMD patients
display progressive muscle weakness leading to the loss
of independent mobility in young adolescents and
respiratory and heart failure in young adults. While
gene, cell, and pharmacological therapies have all been
investigated [2, 3], there is currently no curative ther-
apy for DMD. However, several issues such as efficacy
of studied drugs, locoregional or systemic medication
pathways or dosage, remain to be further explored. The
preclinical DMD model of choice is the dystrophin-
deficient golden retriever muscular dystrophy (GRMD)
dog, which closely mimics many aspects of the human
disease [4, 5]. Scale is a key factor that influences the
translation of data from animal models to humans.
Thus, when studying mechanical impacts, molecular
diffusion and/or cell migration data acquired in GRMD
dogs is much more relevant to human DMD than that
obtained in smaller animal models such as the mdx
mutant mouse [6]. The downside of the GRMD model
is that it is more expensive to purchase and house, and
the use of "man's best friend" for research purposes en-
tails additional political and ethical considerations.
Accordingly, limited numbers of GRMD dogs are gen-
erally used in studies. At first glance, this appears to be
a major impediment to the preclinical evaluation of ther-
apies, particularly given that GRMD dogs exhibit consider-
able inter-individual phenotypic variability [6–8]. However,
there are numerous similarities between canine and
human diseases, and considerable inter-individual vari-
ability is also observed among human patients [9].
Moreover, given the rarity of muscular dystrophies, and
for obvious ethical reasons, clinical studies in man gen-
erally involve limited numbers of patients and pose
similar challenges to those performed in GRMD dogs.
Tools that allow the establishment of better readouts of
disease progression and treatment response are essen-
tial to overcome limitations imposed by small sample
sizes and wide inter-individual variability in studies
using the GRMD model, and to better predict the
pathogenesis of muscular dystrophy and treatment effi-
cacy in humans.
Studies by several groups have conducted gait analysis
in GRMD dogs [10–14]. Using accelerometry analysis in
these animals we have demonstrated less regular and less
powerful acceleration, decreased stride length and fre-
quency, and a redistribution of power from the cranio-
caudal to the medio-lateral axis [11]. Using the main gait
variables, we developed a global gait index that consist-
ently detected early changes in gait patterns in GRMD,
as well as the progressive deterioration of gait quality.
This index was based on the use of principal component
analysis (PCA) and the computation of Euclidean
distances at multiple time points with respect to an age-
matched control group [10]. Given the inherent
complexity of the methodology, we believe that this ap-
proach is not best suited to the problem at hand, and in
fact may hinder the evaluation of therapies in preclinical
studies in GRMD dogs. To increase sensitivity and aid
interpretation of the outcomes, we sought to design a
simpler and more appropriate analytical method using
linear discriminant analysis (LDA). Like PCA, LDA is an
orthogonal transformation and data reduction technique,
but unlike PCA, LDA seeks to minimize intra-group
variance and maximize inter-group variance. Moreover,
LDA yields a predictive model based on control group
data. This is achieved by computation of group member-
ship based on experimental data and assignment rules,
which allow the prediction of group membership for fu-
ture observations. Here, we describe a new method of
3D accelerometric gait analysis using LDA. We discuss
the choice of dependent and independent variables and
describe how to represent the results in a manner that
can be understood by a broad range of users, including
those unfamiliar with LDA. Finally, we demonstrate the
validity of this method by reanalysing data from a previ-
ous study regarding immunosuppressive treatment in
GRMD dogs.
Methods
Subjects
All procedures were carried out in accordance with
Guidelines for the Care and Use of Laboratory Animals,
and approved by the common Ethical Committee of the
National Veterinary School of Alfort, ANSES, and
UPEC. Eight healthy golden retrievers and 20 GRMD
dogs (all males) were included in the study. All animals
came from the French GRMD colony. The healthy dogs
were littermates of some of the GRMD dogs used. Six of
the healthy dogs and 12 of the GRMD dogs had partici-
pated in a previous study [10]. All dogs were housed in
the same facilities, and were genotyped as previously
described [15]. Only the GRMD dogs that were still am-
bulatory after 9 months of age were included in this study.
Evaluation of gait quality using 3D accelerometry
As previously described [11], the 3-dimensional acceler-
ometer recorder used was a Locometrix® gait analysis
system, composed of three orthogonally positioned ac-
celerometers, which can record accelerations along the
dorso-ventral, cranio-caudal, and medio-lateral axes.
Immunosuppressed dogs
To assess the efficiency of our method, we analysed gait
data acquired for four immunosuppressed dogs that had
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been published in a previous paper [12]. These dogs had
been treated with high doses of oral prednisolone (2 mg/
kg/d) and cyclosporine A (initial dose of 20 mg/kg/d)
between 2 and 9 months of age.
Gait testing
Dogs were carried from the kennel to a 45-meter-long
testing corridor located close to the laboratory facilities,
as previously described [10]. The belt to which the accel-
erometric device was attached was fastened around the
thorax of the dog, near the centre of gravity at rest. Each
animal was tested twice per month from 2 months of
age (when motor clinical signs appear in animals that
survive the neonatal period) to 9.5 months of age, thus
covering the period of growth and disease progression
[4]. To enhance the discriminatory power of the method,
values obtained for GRMD dogs that survived to
12 months were also included in the analysis. Young
puppies were familiarized with the corridor and the belt
before the test. The height at withers (HW) was mea-
sured at the end of each test. All tests were performed
by the same experimenter (IB). In each test, the dog was
encouraged to walk or run at its preferred gait, and its
speed calculated over a distance of five meters, as previ-
ously described [11].
Data analysis
For quadrupedal gait analysis, acceleration curves were
analysed using the software provided by the manufac-
turer of the recording device (Equimetrix®, Centaure
Metrix, Evry, France). A 10-second sequence of steady-
state locomotion, which was easily identifiable in the
dorso-ventral acceleration curves, was analysed. The fol-
lowing variables, which have been previously described
in detail [10, 11], were computed: stride frequency (SF,
/s), stride regularity (Reg, dimensionless), total power of
accelerations (TP, W/kg), relative components of the
total power along the three axes (%) (calculated by divid-
ing cranio-caudal (CCP), dorso-ventral (DVP), or medio-
lateral power (MLP) by total power (TP)), and stride
length (calculated by dividing the speed by SF), which
was normalized to height at withers (SL/HW) in order
to circumvent the effect of limb length on this variable.
For the sake of consistency, only observations with a
Reg value >70 were considered for analysis. Gait testing
consisted of two consecutive round trips in the corri-
dor. However, in contrast to healthy dogs, it was very
difficult, if not impossible, for some GRMD dogs to
complete the second round trip.
Discriminant analysis
The main objective of the present study was to assess
the capacity of discriminant analysis (DA) to evaluate
gait, detect functional alterations, and evaluate treatment
benefits during the growth period in GRMD dogs. We
used gait data obtained from healthy and GRMD dogs
and performed DA using XLSTAT software (Addinsoft™).
This Excel add-in extends the analytical functions of
Excel and covers the key requirements for data analysis
and statistics. DA is a commonly used multivariate data
analysis method. The aim of this supervised method is
to predict group memberships of a set of individuals
based on multivariate data. In this scenario, the groups
of individuals are assumed to be known a priori. DA re-
duces the dimensionality of the data at hand by comput-
ing synthetic variables, often called canonical variables
or factors, the aim of which is to maximize inter-group
variance while minimizing intra-group variance. DA
yields new variables, which are linear combinations of
the original variables. The maximum number of such
variables is equal to the number of groups minus one
and are usually noted F1 to F(n-1) where n is the num-
ber of groups. However, in practice, only the first few
canonical variables are used for the purpose of discrim-
ination, since the remaining canonical variables may be
predominantly associated with noise present in the data.
The graphical displays generated using the retained ca-
nonical variables are useful to depict the separation of
groups. DA methods include linear DA (LDA) and quad-
ratic DA (QDA) [16]. LDA is a parametric method that
assumes Gaussian distributions with the same variance-
covariance matrix within the various groups. In practice
however, this is often not the case. Nonetheless, even in
the case of a slight deviation from this requirement,
LDA performs reasonably well [17], and was thus the
method selected for the present study.
Results
Discriminant analysis
We first investigated whether LDA can distinguish the
gait phenotype of GRMD dogs from that of healthy con-
trols independently of age, as previously shown using
PCA [11]. To this end, using the same variables previ-
ously analysed by PCA, we performed LDA with geno-
type (GRMD or Healthy) as the dependent variable. The
characteristics of this first model (Model 1) are listed in
Fig. 1. Because only two groups were included, only one
canonical variable (F1) was calculated. As shown in the
factor-loading chart (Fig. 1b), the main discriminant var-
iables were TP and SL/HW (positively correlated with
the canonical variable) and MLP/TP (negatively corre-
lated with the canonical variable). GRMD and healthy
dogs were highly discriminated using Model 1. The ac-
curacy of the model was assessed using a leave-one-out
cross-validation approach, which revealed a low rate of
misclassification <1%.
To better characterize gait alterations and improve the
evaluation of treatment benefits at different disease
Fraysse et al. BMC Musculoskeletal Disorders  (2017) 18:153 Page 3 of 9
stages, we expanded the dependent variable (GRMD or
Healthy) by defining various age categories. Specifically,
each group (GRMD and Healthy) was subdivided into
age categories (expressed in months), for a total of 32
groups. As data were acquired twice monthly, the time
interval classification was set to 0.5 months. Thus, data
obtained for GRMD and healthy dogs were classified in
groups GRMD_2 to GRMD_12 and groups Healthy_2 to
Healthy_9.5, respectively. LDA was applied to this new
scenario (Model 2). The results revealed that 96.4% of
the variance was explained by the two first canonical
variables (F1 and F2). The outcomes of Model 2 are
shown in Fig. 2. Model 2 was less discriminant for gait
phenotype than Model 1. Indeed, the 95% confidence el-
lipses calculated for GRMD dogs of up to 6.5 months of
age partially overlapped with those calculated for the
2 month-old Healthy group (Fig. 2a). Accordingly, the
rate of misclassification was very high (83.2%). The rate
of misclassification was relatively low (1.2%) when
phenotype was considered independently of age. The
factor-loading chart (Fig. 2b) shows that F1 was mainly
positively correlated with TP and SL/HW whereas F2
was mainly positively correlated with SF and negatively
correlated with MLP/TP. All GRMD centroid coordi-
nates were negative on the F1 axis, while all Healthy
centroids were positive. F1 showed a high canonical
Fig. 1 LDA Model 1: analysis of gait accelerometry parameters in healthy and GRMD dogs a Box and whisker diagrams of canonical variable F1
coordinates calculated by linear discriminant analysis of gait accelerometry parameters in healthy (green) and GRMD (red) dogs with genotype as
the dependent variable. b Factor loading chart. SF, stride frequency; Reg, regularity; TP, total power; CCP/TP, cranio-caudal power normalized to
TP; DVP/TP, dorso-ventral power normalized to TP; MLP/TP, medio-lateral power normalized to TP; SL/HW, stride length normalized to height
at withers
A B
Fig. 2 LDA Model 2: analysis of gait accelerometry parameters in healthy and GRMD dogs. a Linear discriminant analysis of gait accelerometry
parameters for healthy and GRMD dogs with genotype and age (in months) as dependent variables. Individual measurements (dots) and groups
(centroids and 95% confidence ellipses) are positioned on the plane using their values for the two first canonical variables, F1 and F2. Green and
red colours correspond to healthy and GRMD dogs, respectively. For clarity, only the groups of younger and older animals were indicated for
each genotypes. Arrows illustrate the evolution of class centroids according to age. The percentage variance explained by each canonical variable
is indicated in parentheses. b Factor loading chart of F1 and F2 canonical variables. SF, stride frequency; Reg, regularity; TP, total power; CCP/TP,
cranio-caudal power normalized to TP; DVP/TP, dorso-ventral power normalized to TP; MLP/TP, medio-lateral power normalized to TP; SL/HW,
stride length normalized to height at withers
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correlation of 0.95, indicating that in Model 2, as ob-
served in Model 1, F1 was discriminant for phenotype.
For both the GRMD and Healthy groups, the centroid
coordinates on the F2 axis were inversely proportional
to age, indicating that F2 is associated with age and dis-
ease progression. Finally, a low canonical correlation of
0.78 was calculated for F2 in Model 2.
To improve the descriptive properties of the model
while keeping its predictive capabilities, in addition to
including age (in months) as a dependent variable, age
(in days) was also included as an explanatory (or inde-
pendent) variable in the LDA analysis. In this new model
(Model 3), the two first canonical discriminant factors
accounted for 99.7% of variance (Fig. 3). As expected,
Model 3 was discriminant for data points reflecting age
in days. In contrast to Healthy centroids, all GRMD cen-
troids were negative on the F2 axis, indicating that F2
was discriminant for gait phenotype. The factor-loading
chart (Fig. 3b) shows that F2 was predominantly and
positively correlated with TP and SL/HW and negatively
correlated with MLP/TP, whereas F1 was predominantly
and positively correlated with age (in days) and nega-
tively correlated with SF. After 2 months of age, no con-
fidence ellipse overlap was observed between genotypes.
While overlapping was still observed between confidence
ellipses within each genotype group, this was limited to
immediately contiguous age groups. The overall mis-
classification error for Model 3 was less than 12% and as
low as 0.9% when phenotype was considered independ-
ently of age.
Blind test for model validation
The models described in the present study were gener-
ated using accelerometric data from GRMD and healthy
dogs from which measurements had been acquired every
15 days between 2 months of age and 9.5 (healthy dogs)
or 12 (GRMD dogs) months of age. A dataset was gener-
ated as follows: numbers were randomly attributed, by
an external scientist blinded to the data, to each of the
dogs used to set up the model, and to a group of healthy
and GRMD dogs for which only some measurements
were available for the period of interest (2–12 months of
age). Since all these animals were from the French
GRMD colony, we used Model 3 to predict the gait type
of each numbered dog at each time point for which data
was available. The average probability of the dog be-
longing to the Healthy group was calculated for each
time point and then summed. The following classifica-
tion rule was applied: if the sum obtained was >0.95,
the gait was considered that of a healthy dog, while if
the value was <0.05, the gait was considered that of a
GRMD dog. Values of between 0.05 and 0.95 were
considered indicative of an intermediate gait pheno-
type. Finally, gait patterns were attributed to healthy
or GRMD dogs, when the results for more than half of
the time points corresponded to healthy or GRMD
gaits, respectively. The results obtained are presented
in Fig. 4. Of the 81 dogs tested, the predicted gait
phenotype matched the actual phenotype and geno-
type in all cases but one, for which the results were
inconclusive.
A B
Fig. 3 LDA Model 3: analysis of gait accelerometry parameters in healthy and GRMD dogs. a Linear discriminant analysis plot of gait accelerometry
parameters for healthy and GRMD dogs with genotypes and age in months as dependent variables, and age in days as an additional explanatory
variable. Individual measurements (dots) and groups (centroids and 95% confidence ellipses) are positioned on the plane using their values for the two
first canonical variables, F1 and F2. Green and red colours correspond to healthy and GRMD dogs, respectively. For clarity, only the groups of younger
and older animals were indicated for each genotypes. Arrows illustrate the evolution of class centroids according to age. The percentage variance
explained by each canonical variable is indicated in parentheses. b Factor loading chart of F1 and F2 canonical variables. SF, stride frequency; Reg,
regularity; TP, total power; CCP/TP, cranio-caudal power normalized to TP; DVP/TP, dorso-ventral power normalized to TP; MLP/TP, medio-lateral power
normalized to TP; SL/HW, stride length normalized to height at withers
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Model validation
A previous study by some members of our group tested
the effects of immunosuppressive treatments (oral ad-
ministration of cyclosporine A and corticosteroids) on
muscular dystrophy and overall health in GRMD dogs
[12]. We reanalysed the experimental data from this pre-
vious study using our new methodology. Furthermore,
we designed a new means of representing the outcomes
that allows easier interpretation of the results (Fig. 5).
Fig. 4 Gait phenotype separation: blind testing of LDA Model 3.
To validate our proposed methodology, we used a blind dataset
pertaining to 81 dogs and investigated the capability of Model 3 to
predict genotype based on gait assessment. Each row corresponds
to an individual dog and each column to a specific time point (age).
Colours denote predicted phenotype based on the results of gait
analysis. Green, red, and yellow correspond, respectively, to gait
patterns that resemble that of healthy dogs (p > 95%), are strictly
different to that of healthy dogs but similar to that of GRMD dogs
(p > 95%), and are strictly different to the gait patterns of both
healthy (p < 5%) and GRMD dogs (p < 5%). Grey colour indicates that
measurements were not available. Cells of the penultimate column,
entitled Predicted, are coloured to reflect the predominant phenotype
(Healthy or GRMD) predicted by the model for each dog. Thus,
green and red cells indicate that the gait of the corresponding dog
resembles that of a healthy and a GRMD dog, respectively. n.c.
denotes an inconclusive prediction result. Cells in the rightmost
column are coloured according to the actual genotype of the dog
Fig. 5 LDA Model 3 as a tool for evaluating the effects of
immunosuppressive treatment on gait in GRMD dogs.
Immunosuppressive treatment has beneficial effects on gait in
GRMD dogs. Using Model 3, curves were generated by plotting
centroids, and the associated 95% confidence intervals, corresponding
to healthy, untreated GRMD, and immunosuppressant-treated GRMD
dogs on F1 and F2 axes. Centroids corresponding to GRMD-
immunosuppressed dogs are colour-coded to reflect their comparison
with the healthy group: green, similar to healthy gait (p > 0.95); yellow,
intermediate gait (0.95 > p > 0.05), red, similar to GRMD gait (p < 0.05).
For a more comprehensive representation, the projection of the age in
days axe on the factorial plan was calculated and added as the upper
axe (see text)
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We calculated the projection of the age (in days) axis
and added it to the figure. In this way, the representation
remains rigorous from a statistical point of view, show-
ing F1 and F2 axes, but allows the reader to also refer to
age of the dogs. Moreover, using the membership prob-
abilities calculated by LDA, we applied a colour code to
indicate on the graph to which gait type the data points
should correspond: green, red, and yellow were applied
to healthy, GRMD, and intermediate groups, respect-
ively, as predicted by the assignment rule based on the
mean of the probabilities (described above). This repre-
sentation allows rapid assessment of the evolution of the
gait of given dogs or group of dogs in comparison with
that of other healthy or GRMD dogs. As shown in Fig. 5,
immunosuppression in GRMD dogs had a significant
beneficial effect on gait, although this was both partial
and temporary.
Discussion
We previously demonstrated that PCA, although a non-
supervised analysis strategy, can distinguish the gait
phenotype of GRMD dogs from that of healthy controls
with reasonable accuracy, and does so independently of
age [11]. We show in the present study that similar re-
sults could be obtained using LDA. However, when the
age of the dogs were not take into account, the model
built using LDA (Model 1) was found not to adequately
represent the progression of the disease, which evolves
over the course of the postnatal growth phase. On the
other hand, addition of age, in months, as a supplemen-
tary dependent variable in LDA, the model obtained
(Model 2) exhibited a very high rate of misclassification.
This likely reflected the slow rate of disease progression
over the short age intervals analysed.
Nonetheless, in Model2, the discriminant axis mainly
associated with age and disease progression, F2, presented
a low canonical correlation, indicating that the model was
not sufficiently sensitive to accurately evaluate the impact
of progressive dystrophy on gait in growing GRMD dogs.
One means of improving the model was to increase the
age interval (e.g. from 0.5 to 1 month), which would cer-
tainly reduce the misclassification error, but would also
decrease the sensitivity of the model. The aim of this study
was not to demonstrate altered gait in GRMD versus
healthy dogs, but rather to develop a method to better
identify gait alterations and their progression with age in
GRMD dogs. To improve the descriptive properties of the
model while keeping its predictive capabilities, we have ar-
tificially stretched the model (Model 3) in the direction of
the progression of age, by introducing age (in days) as an
explanatory (or dependent) variable in the LDA analysis,
in addition to including age (in months) as a dependent
variable. The dogs included in the study were not born on
the same day. Additionally, sometimes some dogs were
not able to walk, thus their acquisition session was de-
layed. By contrast, acquisition sessions were always done
on the same day of the week, every 15 days. Thus, the age
of the animals in days in the same age group in months
could vary from about 7 days. The intrinsic variability of
the age in days spread the model in the factorial plan help-
ing to discriminate the different groups of age, although it
could be assumed that this variability does not signifi-
cantly impact the measurements. In Model 3, the two first
canonical discriminant factors, F1 and F2, accounted for
99.7% of variance. F1 was predominantly correlated with
age whereas F2 was discriminant for gait phenotype.
Model 3 presented a low overall misclassification error
and high canonical correlations of 0.99 and of 0.95 were
calculated for F1 and F2, respectively.
In order to investigate further the suitability of Model
3 as a tool for gait analysis in preclinical studies with
GRMD dogs, we used it to predict the genotypes of a co-
hort of 81 healthy and GRMD dogs starting from their
gait accelerometry characteristics. For each dog of the
cohort, a number was randomly attributed by an exter-
nal scientist blinded to the data. Using this approach,
when “the data were unblinded”, the predicted gait
phenotype matched the actual phenotype and genotype
in all cases but one. These findings strongly support the
robustness and accuracy of the method.
Some members of our group tested, in a previous
study, the effects of immunosuppressive treatments (oral
administration of cyclosporine A and corticosteroids) on
muscular dystrophy and overall health in GRMD dogs
[12]. Indeed, immunomodulatory treatments have been
employed in several studies assessing the effectiveness of
gene, cell, or pharmacological therapies in dog models of
DMD to supress the immune response to the viral vec-
tor, donor cells, and/or the transgene product [18–20].
The obtained results vary considerably depending on the
variables measured. Although Barthélémy and colleagues
[12] reported a more severe disease progression in terms
of isometric force and histology, they also found an im-
provement in gait classification using a PCA-based gait
index calculated from the seven accelerometric variables
used in the present study. This longitudinal analysis was
complex, as PCA, unlike DA, is an unsupervised
approach. The authors performed PCA for each age cat-
egory and calculated the corresponding Euclidean
distance for each GRMD dog to the centroid of age-
matched healthy dogs, and, thereafter, plotted the evolu-
tion of this distance with age. Using Model 3, we found
that immunosuppression in GRMD dogs had a signifi-
cant beneficial effect on gait, although this was both par-
tial and temporary. This finding was in line with those
of Barthélémy and coworkers [12]. Furthermore, LDA
revealed that significant effects of treatment on gait ob-
served at 4 months of age were preceded by signs of
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improvement that were evident as early as 3 months,
supporting the sensitivity of our model.
Conclusion
Using LDA we have generated a highly sensitive model of
gait alterations due to muscular dystrophy in the GRMD
dog. Our model shows a high degree of discriminatory ac-
curacy, distinguishing the gait phenotype of GRMD dogs
from that of healthy dogs as early as 2.5 months of age,
and thus overcoming some of the difficulties in analysing
a progressive disease that occurs during the growth phase
of postnatal development. Moreover, we designed a new
means of representing the outcomes of our analysis that
allows for easier interpretation of the results. This is a key
strength of our study: because preclinical results are the
base upon which phase 1/2 clinical trials in human pa-
tients are prepared and designed, preclinical outcomes
should be completely understandable to all those involved
in the design and the testing of potential treatments from
preclinical through to clinical phases. In our experience,
graphical displays depicting only the two variables (F1 and
F2) are very likely to be unclear, and sometimes mislead-
ing, to practitioners unfamiliar with DA or PCA.
We previously demonstrated that accelerometry com-
bined with PCA constitutes a reliable follow-up tool for
gait analysis in preclinical therapeutic trials using GRMD
dogs. However, this approach has some limitations, in-
cluding limited sensitivity, and high complexity of the
data generated. The model presented here greatly im-
proves upon this method by employing LDA.
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